{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:31:59Z","timestamp":1793705519027,"version":"4.5.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T00:00:00Z","timestamp":1523232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"European Horizon's 2020 Research and Innovation Programme under the Marie Sklodowska-Curie","award":["642609"],"award-info":[{"award-number":["642609"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ijpddr.2018.04.001","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T22:05:40Z","timestamp":1523484340000},"page":"223-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome\u00ae and AmBisome\u00ae in murine cutaneous leishmaniasis"],"prefix":"10.1016","volume":"8","author":[{"given":"Gert-Jan","family":"Wijnant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-5282","authenticated-orcid":false,"given":"Katrien","family":"Van Bocxlaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Alavijeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Silva-Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5512-9093","authenticated-orcid":false,"given":"Sandra","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-4643","authenticated-orcid":false,"given":"Isabel","family":"Mauricio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudaxshina","family":"Murdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon L.","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2018.04.001_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Adler-Moore","year":"2016","journal-title":"Med. Mycol."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2018.04.001_bib3","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1093\/cid\/ciw670","article-title":"Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH)","volume":"63","author":"Aronson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4269\/ajtmh.16-0631","article-title":"Case report: treatment of widespread nodular post kala-azar dermal leishmaniasis with extended-dose liposomal amphotericin B in Bangladesh: a series of four cases","volume":"97","author":"Basher","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s12639-014-0607-3","article-title":"Treatment of visceral leishmaniasis: anomalous pricing and distribution of AmBisome and emergence of an indigenous liposomal amphotericin B, FUNGISOME","volume":"40","author":"Bhattacharya","year":"2016","journal-title":"J. Parasit. Dis."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0035-9203(99)90036-6","article-title":"Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis","volume":"93","author":"Bodhe","year":"1999","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib8","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s11095-008-9562-y","article-title":"Role of particle size in phagocytosis of polymeric microspheres","volume":"25","author":"Champion","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.ijpddr.2018.04.001_bib9","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00878-16","article-title":"The role of signaling via aqueous pore formation in resistance responses to amphotericin B","volume":"60","author":"Cohen","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib10","series-title":"Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India","first-page":"27","author":"Desjeux","year":"2013"},{"key":"10.1016\/j.ijpddr.2018.04.001_bib11","unstructured":"Drug Approval Package: Ambisome (Amphotericin B) NDA# 050740 [WWW Document], n.d. URL https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/050740_ambisome_toc.cfm (accessed 11.16.2017)."},{"issue":"Suppl 1","key":"10.1016\/j.ijpddr.2018.04.001_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.suppl_1.31","article-title":"Overview of the lipid formulations of amphotericin B","volume":"49","author":"Dupont","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/0035-9203(87)90011-3","article-title":"Topical treatment of New and Old World cutaneous leishmaniasis in experimental animals","volume":"81","author":"El-On","year":"1987","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5639\/gabij.2013.0202.022","article-title":"Access to liposomal generic formulations: beyond AmBisome and Doxil\/Caelyx","volume":"2","author":"Gaspani","year":"2013","journal-title":"Generics and Biosimilars Initiative Journal"},{"key":"10.1016\/j.ijpddr.2018.04.001_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/jac\/32.1.133","article-title":"Pharmacokinetics and tolerance of liposomal amphotericin B in patients","volume":"32","author":"Gokhale","year":"1993","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4269\/ajtmh.14-0657","article-title":"Short-course treatment regimen of indian visceral leishmaniasis with an indian liposomal amphotericin B preparation (Fungisome\u2122)","volume":"94","author":"Goswami","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006094","article-title":"Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: not a panacea","volume":"11","author":"Guery","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1039\/C5CS00674K","article-title":"New approaches from nanomedicine for treating leishmaniasis","volume":"45","author":"Guti\u00e9rrez","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/0250-474X.89757","article-title":"Formulation and evaluation of long circulating liposomal amphotericin B: a scinti-kinetic study using 99mTc in BALB\/C mice","volume":"73","author":"Jadhav","year":"2011","journal-title":"Indian J. Pharmaceut. Sci."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib20","article-title":"Different liposomal amphotericin B formulations for visceral leishmaniasis\u2013Author\u2019s reply","volume":"2","author":"Kshirsagar","year":"2014","journal-title":"The Lancet Global Health"},{"issue":"Suppl 1","key":"10.1016\/j.ijpddr.2018.04.001_bib21","first-page":"S5","article-title":"Liposomal drug delivery system from laboratory to clinic","volume":"51","author":"Kshirsagar","year":"2005","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib22","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1128\/AAC.01586-09","article-title":"Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis","volume":"54","author":"Lestner","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib23","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2214-109X(13)70118-9","article-title":"Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study","volume":"2","author":"Mondal","year":"2014","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.ijpddr.2018.04.001_bib24","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1371\/journal.pntd.0000764","article-title":"A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy","volume":"4","author":"Mondal","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/pim.12007","article-title":"Tissue damage and immunity in cutaneous leishmaniasis","volume":"34","author":"Nyl\u00e9n","year":"2012","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib27","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2217\/nnm.14.237","article-title":"Comparison of nanoparticle penetration into solid tumors and sites of inflammation: studies using targeted and nontargeted liposomes","volume":"10","author":"Poh","year":"2015","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.ijpddr.2018.04.001_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/trstmh\/tru011","article-title":"Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients","volume":"108","author":"Rocio","year":"2014","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1517\/17425247.5.7.805","article-title":"Drug delivery systems against leishmaniasis? Still an open question","volume":"5","author":"Romero","year":"2008","journal-title":"Expet Opin. Drug Deliv."},{"issue":"Suppl 1","key":"10.1016\/j.ijpddr.2018.04.001_bib31","first-page":"S58","article-title":"Post-marketing study to assess the safety, tolerability and effectiveness of Fungisome: an Indian liposomal amphotericin B preparation","volume":"51","author":"Sanath","year":"2005","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri.2016.72","article-title":"Cutaneous leishmaniasis: immune responses in protection and pathogenesis","volume":"16","author":"Scott","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/2211738501999131118125018","article-title":"Amphotericin B formulations \u2013 the possibility of generic competition","volume":"1","author":"Serrano","year":"2013","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4269\/ajtmh.14-0259","article-title":"Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study","volume":"92","author":"Sundar","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/AAC.31.3.421","article-title":"Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B","volume":"31","author":"Szoka","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib36","doi-asserted-by":"crossref","first-page":"15344","DOI":"10.1073\/pnas.1411499111","article-title":"Investigating the optimal size of anticancer nanomedicine","volume":"111","author":"Tang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib37","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jphp.12802","article-title":"Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis","volume":"69","author":"Tonin","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/JCM.01416-07","article-title":"Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites","volume":"46","author":"van der Meide","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00497-17","article-title":"Pharmacodynamics and biodistribution of single-dose liposomal amphotericin B at different stages of experimental visceral leishmaniasis","volume":"61","author":"Voak","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib40","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.42.9.2391","article-title":"Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients","volume":"42","author":"Walsh","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00358-17","article-title":"Efficacy of paromomycin-chloroquine combination therapy in experimental cutaneous leishmaniasis","volume":"61","author":"Wijnant","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02009-17","article-title":"Relation between skin pharmacokinetics and efficacy in AmBisome treatment of murine cutaneous leishmaniasis","volume":"62","author":"Wijnant","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib43","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","article-title":"Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.04.001_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"3","author":"Zijlstra","year":"2003","journal-title":"Lancet Infect. Dis."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320718300101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320718300101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:49:14Z","timestamp":1761922154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320718300101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S2211320718300101"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2018.04.001","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome\u00ae and AmBisome\u00ae in murine cutaneous leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2018.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}